Premium
Linkage map of a region of human chromosome band 11q13 amplified in breast and squamous cell tumors
Author(s) -
Brookes Sharon,
Alistair Lammie G.,
Dickson Clive,
Peters Gordon,
Schuuring Ed
Publication year - 1992
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.2870040404
Subject(s) - biology , cpg site , chromosome band , gene , dna , cancer , chromosome , cell , chromosomal translocation , cancer research , genetics , microbiology and biotechnology , gene mapping , dna methylation , gene expression
DNA amplification involving markers on human chromosome band 11q13 is a consistent feature of several major cancers, notably adenocarcinoma of the breast and squamous cell carcinoma of the head, neck, lung, and esophagus. Since the presence of the amplification may be clinically significant, by defining a subset of patients at increased risk, it is important to establish which of the several genes on the amplified DNA provides the selective force. Here we describe a physical map of the centromeric end of the amplified DNA as it exists in a particular squamous carcinoma cell line (UMSCC2) and establish an unambiguous order for several known markers in the region, including pMSS1/D11S97, pHB159/D11S146, BCL1, PRAD1 /D11S287, HSTFI/FGF4 and INT2/FGF3. Significantly, PRAD1 is within 120–150 kb of the BCL1 translocation breakpoint and the data identify a new CpG island (D11S814) between PRAD1 and HSTFI. The ordering of the HSTFI and INT2 genes and the clustering of CpG islands in the region have important implications in assessing whether the frequently observed amplifications at 11q13 are centered on one or more genes.